AbbVie's key product revenues 2022-2023

AbbVie is an international pharmaceutical company with a multitude of pharmaceutical products available. In 2023, once again, the company’s top revenue generating drug was Humira. In that year, Humira generated about 14.4 billion U.S. dollars in revenue for AbbVie. That amount was significantly lower than in previous years, due to generic versions entering the market. Humira is used to treat several types of autoimmune diseases including certain types of arthritis and Crohn’s disease.

AbbVie’s company profile

Abbvie was founded in 2013, originally a spin-off of Abbott Laboratories, and is based out of Chicago, Illinois, in the United States. In recent years the company has experienced some growth which can also be seen in their increasing number of employees. The company has also experienced exceptional growth in their annual revenues. Finally, AbbVie has experienced significant growth in its total assets in recent years. However, 2023 showed some stagnating tendencies for the company.

AbbVie’s global positioning

Despite being a young company, AbbVie is among the top pharmaceutical companies. AbbVie is placed among other top companies such as Pfizer and Johnson & Johnson in terms of their prescription sales and expenditure on research and development. The company is also among the top pharmaceutical companies in terms of its net profits per employee.